Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotorasib - Amgen

Next Previous
Drug Profile

Sotorasib - Amgen

Alternative Names: AMG-510; LUMAKRAS; LUMYKRAS

Latest Information Update: 10 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen; Carmot Therapeutics
  • Developer Amgen; BeOne Medicines; REVOLUTION Medicines; Verastem Oncology
  • Class Antineoplastics; Piperazines; Pyridines; Pyridones; Pyrimidines; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer; Colorectal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Non-small cell lung cancer
  • Phase III Solid tumours
  • Phase I/II Brain metastases; Pancreatic cancer

Most Recent Events

  • 09 Feb 2026 Amgen completes phase-I CodeBreaK 105 trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in Hong Kong, Taiwan (PO) (NCT04380753)
  • 02 Jan 2026 Phase-II clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease) in Taiwan (PO) (NCT07172919)
  • 02 Jan 2026 Phase-II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Second-line therapy or greater) in Taiwan (PO) (NCT07172919)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top